MAHA's Struggle with Identity: Corporate Connections Versus Community Origins
- Robert F. Kennedy Jr.'s MAHA movement faces internal fractures as corporate partnerships and policy shifts alienate grassroots supporters. - Critics accuse the administration of abandoning anti-vaccine roots through $500M funding cuts and collaborations with biotech firms like Eli Lilly . - Former allies condemn MAHA's "identity crisis," while 67% public support persists despite warnings about coalition dilution from experts. - Kennedy defends pragmatic alliances as necessary for governance, but faces pr
Robert F. Kennedy Jr.'s "Make America Healthy Again" (MAHA) initiative, which once brought together anti-vaccine proponents and environmentalists, is now experiencing internal divisions due to conflicting goals and involvement with corporations. Grassroots members claim the leadership has abandoned its original mission, while Kennedy and his supporters argue that adapting to the realities of leadership is necessary to broaden the movement’s impact.
This discord became especially apparent this week as Kennedy was criticized by former supporters and dismissed staff. Gray Delany, who was removed from his position at the Department of Health and Human Services (HHS) in August, expressed on a podcast, "
The administration's balancing act has drawn further scrutiny.
Kennedy has sought to quell dissent, defending figures like White House Chief of Staff Susie Wiles and adviser Stefanie Spear against conspiracy theories suggesting they are undermining his agenda. "
Public support for MAHA remains robust, with two-thirds of Americans endorsing the initiative in a June Ipsos poll.
As MAHA navigates its identity crisis, Kennedy's ability to reconcile idealism with political pragmatism will determine whether the movement remains a force for change-or splinters into irrelevance.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Polkadot Latest Updates: ECB Raises Concerns: Cryptocurrency and Stock Market Downturns Resemble Dot-Com Bubble Threats
- ECB warns U.S. equity/crypto corrections threaten stability, urging central banks to retain rate-cut flexibility amid market volatility. - JPMorgan links crypto ETF outflows to retail investor behavior, noting $4B November sales contrast with $96B equity ETF inflows. - U.S. Treasury downplays recession risks, citing 2026 growth optimism despite shutdown impacts and services-driven inflation. - MSCI highlights tech valuation risks akin to dot-com era, while DeFi faces $12B liquidity crisis with 95% capita

Novartis Increases 2030 Growth Projections Despite Analysts' Concerns About Patent Threats
- Novartis raised 2030 sales growth targets to 5-6% annually, driven by high peak sales expectations for oncology drugs Kisqali and Scemblix. - CEO Vas Narasimhan highlighted eight de-risked drugs with $3-10B peak potential, but analysts warned of patent expirations and uncertain pipeline progress beyond 2030. - Shares rose 0.5% post-announcement, while Exact Sciences surged 17% on its $105/share acquisition by Abbott and Samsung Biologics saw a 71% valuation re-rating after spin-off. - J.P. Morgan caution

Institutional Blockchain Integration: Blockdaemon and 21shares Bridge Traditional Finance and Web3 through the Canton Network
- Blockdaemon's Institutional Vault now supports Canton Coin, enabling secure custody and tokenization for institutions on the Canton Network. - 21shares launched a Canton Coin ETP on Euronext, offering investors institutional-grade exposure to privacy-focused blockchain innovation. - Canton Network's architecture, backed by J.P. Morgan and Goldman Sachs , facilitates secure, interoperable transactions while maintaining regulatory compliance. - Partnerships between blockchain infrastructure providers and t

LINK Price Moves to $13.90 as Market Tracks Tight Short-Term Structure
